FDA Clearance Tracker · K173839
Tissue of Origin Test Kit-FFPE
Last checked: Nov 20, 2026Latest source record: Mar 15, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Mar 15, 2018
Substantially Equivalent
Time to decision
87 days
Received Dec 18, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K173839
- Device name
- Tissue of Origin Test Kit-FFPE
- Applicant
- Cancer Genetics, Inc.
- Applicant location
- Los Angeles, CA
- Received
- Dec 18, 2017
- Decided
- Mar 15, 2018
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device class
- Class II
- Regulation
- 21 CFR 862.3100
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code OIW. The earliest in FDA's data is K080896, decided Jul 30, 2008.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K173839
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Cancer Genetics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.